New combo therapy could help more liver cancer patients get transplants
NCT ID NCT07059494
First seen Nov 05, 2025 · Last updated Apr 30, 2026 · Updated 32 times
Summary
This study tests whether combining two drugs (atezolizumab and bevacizumab) with a type of internal radiation (Y90) can shrink liver tumors enough for patients to qualify for a liver transplant. About 40 adults with liver cancer will receive this treatment. The goal is to see if the tumors shrink or if patients' tumor markers drop enough to make them eligible for transplant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Icahn School of Medicine at Mount Sinai
RECRUITINGNew York, New York, 10029, United States
Contact
Conditions
Explore the condition pages connected to this study.